Stelios Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Stelios Therapeutics, Inc.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
PainReform licenses Encore's post-surgical pain product
The pain management company PainReformhas entered into its first major licence agreement by signing a deal withEncore Therapeutics, which gives the Israeli firm exclusive North American rights to Encore's post-surgical pain product, ETI-211, as well as the option to expand the agreement to other countries including Japan and the EU.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- GenStem Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.